| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 21 | 2017 | 557 | 2.230 |
Why?
|
| Fenretinide | 7 | 2009 | 16 | 1.040 |
Why?
|
| Carcinoma, Transitional Cell | 10 | 2011 | 197 | 0.970 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 4 | 2011 | 57 | 0.720 |
Why?
|
| Antineoplastic Agents | 14 | 2020 | 1695 | 0.690 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 118 | 0.630 |
Why?
|
| Receptors, Retinoic Acid | 3 | 2005 | 100 | 0.600 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2017 | 667 | 0.600 |
Why?
|
| Prostatic Neoplasms | 11 | 2006 | 1547 | 0.550 |
Why?
|
| Cyclooxygenase 2 | 8 | 2008 | 155 | 0.530 |
Why?
|
| Myasthenia Gravis | 1 | 2017 | 73 | 0.530 |
Why?
|
| Isoenzymes | 5 | 2004 | 231 | 0.520 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 129 | 0.500 |
Why?
|
| Prostate | 5 | 2006 | 434 | 0.500 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2011 | 1143 | 0.470 |
Why?
|
| Hepatitis B, Chronic | 4 | 2020 | 79 | 0.470 |
Why?
|
| Anticarcinogenic Agents | 4 | 2004 | 56 | 0.450 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 259 | 0.450 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 6 | 2005 | 83 | 0.450 |
Why?
|
| Lung Neoplasms | 7 | 2022 | 1662 | 0.450 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2004 | 59 | 0.420 |
Why?
|
| PPAR gamma | 5 | 2006 | 88 | 0.420 |
Why?
|
| Neoplasms | 8 | 2020 | 2792 | 0.400 |
Why?
|
| Immunotherapy | 1 | 2017 | 679 | 0.380 |
Why?
|
| Sulfonamides | 2 | 2011 | 270 | 0.380 |
Why?
|
| Urinary Bladder | 4 | 2011 | 241 | 0.370 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 1036 | 0.360 |
Why?
|
| Tretinoin | 4 | 2005 | 117 | 0.360 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2004 | 307 | 0.360 |
Why?
|
| Pyrazoles | 2 | 2011 | 305 | 0.360 |
Why?
|
| Apoptosis | 8 | 2013 | 1805 | 0.350 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2010 | 1893 | 0.350 |
Why?
|
| Urothelium | 3 | 2010 | 60 | 0.330 |
Why?
|
| Selenomethionine | 2 | 2006 | 14 | 0.320 |
Why?
|
| Prostaglandin D2 | 3 | 2005 | 9 | 0.310 |
Why?
|
| Selenium | 2 | 2006 | 22 | 0.300 |
Why?
|
| Head and Neck Neoplasms | 2 | 2023 | 503 | 0.290 |
Why?
|
| Dinoprostone | 2 | 2008 | 77 | 0.290 |
Why?
|
| Virus Activation | 3 | 2020 | 87 | 0.280 |
Why?
|
| Urologic Neoplasms | 1 | 2006 | 42 | 0.250 |
Why?
|
| Receptors, Virus | 1 | 2006 | 107 | 0.250 |
Why?
|
| Respiratory Mucosa | 1 | 2005 | 91 | 0.240 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 354 | 0.220 |
Why?
|
| Humans | 63 | 2023 | 125086 | 0.220 |
Why?
|
| Carcinoma, Embryonal | 1 | 2003 | 3 | 0.220 |
Why?
|
| Cell Line, Tumor | 12 | 2015 | 3349 | 0.210 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2019 | 163 | 0.210 |
Why?
|
| G1 Phase | 1 | 2003 | 67 | 0.210 |
Why?
|
| Adenoviridae | 1 | 2006 | 604 | 0.210 |
Why?
|
| Cell Proliferation | 5 | 2013 | 2312 | 0.200 |
Why?
|
| Retinoids | 2 | 2001 | 34 | 0.200 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2004 | 206 | 0.190 |
Why?
|
| Papillomavirus Infections | 2 | 2019 | 294 | 0.190 |
Why?
|
| Breast | 1 | 2003 | 214 | 0.190 |
Why?
|
| Transcription Factors | 4 | 2011 | 2588 | 0.190 |
Why?
|
| Metformin | 1 | 2023 | 151 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2005 | 725 | 0.180 |
Why?
|
| Transfection | 7 | 2015 | 1068 | 0.180 |
Why?
|
| Down-Regulation | 4 | 2011 | 698 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 9 | 2013 | 1064 | 0.180 |
Why?
|
| Oncogenes | 3 | 1996 | 167 | 0.170 |
Why?
|
| Adenocarcinoma | 2 | 2006 | 1026 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 4 | 2011 | 619 | 0.170 |
Why?
|
| Male | 29 | 2019 | 61463 | 0.160 |
Why?
|
| Hepatitis B virus | 1 | 2020 | 130 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2009 | 1698 | 0.160 |
Why?
|
| Celecoxib | 2 | 2011 | 32 | 0.160 |
Why?
|
| Neoplasm Proteins | 2 | 2010 | 671 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 4 | 2019 | 152 | 0.150 |
Why?
|
| Papillomaviridae | 1 | 2019 | 144 | 0.150 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2019 | 71 | 0.150 |
Why?
|
| Aged | 13 | 2019 | 19861 | 0.150 |
Why?
|
| Blotting, Western | 5 | 2013 | 1103 | 0.150 |
Why?
|
| Genital Neoplasms, Female | 1 | 1998 | 45 | 0.140 |
Why?
|
| Diplopia | 1 | 2017 | 39 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2015 | 1201 | 0.140 |
Why?
|
| Fas Ligand Protein | 2 | 2015 | 33 | 0.140 |
Why?
|
| Phosphoproteins | 2 | 2013 | 417 | 0.130 |
Why?
|
| Fatal Outcome | 1 | 2017 | 359 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-jun | 3 | 2003 | 40 | 0.130 |
Why?
|
| Arachidonate 15-Lipoxygenase | 2 | 2006 | 6 | 0.130 |
Why?
|
| Dyspnea | 1 | 2017 | 152 | 0.130 |
Why?
|
| Breast Neoplasms | 3 | 2003 | 2512 | 0.120 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2015 | 9 | 0.120 |
Why?
|
| Membrane Proteins | 6 | 2005 | 1525 | 0.120 |
Why?
|
| fas Receptor | 1 | 2015 | 41 | 0.120 |
Why?
|
| Gene Expression | 2 | 2011 | 1561 | 0.120 |
Why?
|
| Retinoid X Receptors | 2 | 2005 | 33 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2020 | 752 | 0.120 |
Why?
|
| Isotretinoin | 3 | 2010 | 26 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 6 | 2011 | 1331 | 0.120 |
Why?
|
| B-Lymphocytes | 3 | 2013 | 534 | 0.110 |
Why?
|
| Neoplasm Staging | 5 | 2011 | 1275 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 1290 | 0.110 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 1155 | 0.110 |
Why?
|
| Cell Division | 3 | 2006 | 782 | 0.110 |
Why?
|
| RNA, Messenger | 7 | 2015 | 2820 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2010 | 351 | 0.110 |
Why?
|
| Animals | 19 | 2015 | 34218 | 0.110 |
Why?
|
| Female | 22 | 2018 | 66747 | 0.100 |
Why?
|
| Chemoprevention | 2 | 2003 | 58 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2006 | 684 | 0.100 |
Why?
|
| Orbital Neoplasms | 1 | 2012 | 65 | 0.100 |
Why?
|
| Epidermal Growth Factor | 1 | 2012 | 122 | 0.100 |
Why?
|
| Middle Aged | 13 | 2018 | 26926 | 0.090 |
Why?
|
| Mice, Nude | 4 | 2011 | 708 | 0.090 |
Why?
|
| Quinazolines | 1 | 2012 | 174 | 0.090 |
Why?
|
| Melanoma | 1 | 2019 | 944 | 0.090 |
Why?
|
| Lymphoma, B-Cell | 1 | 2013 | 141 | 0.090 |
Why?
|
| Cell Death | 3 | 2015 | 241 | 0.090 |
Why?
|
| Cell Membrane | 1 | 2013 | 462 | 0.090 |
Why?
|
| Veterans | 2 | 2019 | 1752 | 0.090 |
Why?
|
| Models, Economic | 2 | 2008 | 51 | 0.090 |
Why?
|
| Neurons, Afferent | 2 | 1987 | 50 | 0.090 |
Why?
|
| Neoplasm Grading | 1 | 2011 | 272 | 0.090 |
Why?
|
| Mice | 11 | 2015 | 17632 | 0.090 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 6597 | 0.090 |
Why?
|
| Genes, jun | 2 | 2003 | 9 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2019 | 3456 | 0.080 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 70 | 0.080 |
Why?
|
| Flow Cytometry | 3 | 2013 | 794 | 0.080 |
Why?
|
| Genes, Neoplasm | 1 | 2010 | 80 | 0.080 |
Why?
|
| Carcinoma in Situ | 1 | 2010 | 71 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2011 | 1638 | 0.080 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 2 | 2006 | 6 | 0.080 |
Why?
|
| Sirolimus | 1 | 2011 | 227 | 0.080 |
Why?
|
| Leukoplakia, Oral | 1 | 2009 | 4 | 0.080 |
Why?
|
| Smoking | 2 | 2010 | 1049 | 0.080 |
Why?
|
| DNA Fingerprinting | 1 | 2009 | 107 | 0.080 |
Why?
|
| Hyperplasia | 2 | 2010 | 208 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 573 | 0.080 |
Why?
|
| Survival Rate | 2 | 2011 | 2061 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2010 | 1054 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 512 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 429 | 0.070 |
Why?
|
| Time Factors | 3 | 2006 | 6327 | 0.070 |
Why?
|
| Tissue Distribution | 2 | 2006 | 392 | 0.070 |
Why?
|
| Microsatellite Repeats | 1 | 2009 | 221 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2011 | 474 | 0.070 |
Why?
|
| Administration, Intravesical | 1 | 2008 | 34 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 281 | 0.070 |
Why?
|
| Chickens | 2 | 1987 | 636 | 0.070 |
Why?
|
| Protein Isoforms | 2 | 2005 | 404 | 0.070 |
Why?
|
| Cells, Cultured | 5 | 2005 | 3052 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 1267 | 0.070 |
Why?
|
| Cell Line | 3 | 2008 | 2757 | 0.070 |
Why?
|
| Lidocaine | 1 | 1987 | 46 | 0.070 |
Why?
|
| Prostatectomy | 2 | 2006 | 344 | 0.070 |
Why?
|
| Placebos | 1 | 2008 | 241 | 0.070 |
Why?
|
| BCG Vaccine | 1 | 2008 | 109 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2008 | 1506 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2004 | 1098 | 0.070 |
Why?
|
| HIV Infections | 1 | 2018 | 1897 | 0.070 |
Why?
|
| Neck | 1 | 1987 | 135 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 2 | 2003 | 258 | 0.070 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2006 | 13 | 0.060 |
Why?
|
| Skin Neoplasms | 2 | 2019 | 862 | 0.060 |
Why?
|
| Seminal Vesicles | 1 | 2006 | 55 | 0.060 |
Why?
|
| Nitrobenzenes | 1 | 2006 | 19 | 0.060 |
Why?
|
| Feedback, Physiological | 1 | 2006 | 69 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 930 | 0.060 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2006 | 88 | 0.060 |
Why?
|
| Azacitidine | 1 | 2005 | 53 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2003 | 1498 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 173 | 0.060 |
Why?
|
| Vitamin E | 1 | 2005 | 69 | 0.060 |
Why?
|
| Adult | 7 | 2009 | 29632 | 0.060 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2005 | 60 | 0.060 |
Why?
|
| Keratins | 1 | 2005 | 54 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 5175 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2008 | 372 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2006 | 252 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 1314 | 0.060 |
Why?
|
| Endothelium | 1 | 2004 | 69 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 730 | 0.060 |
Why?
|
| RNA, Neoplasm | 2 | 2010 | 138 | 0.060 |
Why?
|
| Kinetics | 2 | 2003 | 1332 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2018 | 12391 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2005 | 184 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2100 | 0.060 |
Why?
|
| Epithelium | 1 | 2005 | 363 | 0.060 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2004 | 35 | 0.050 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2004 | 63 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2004 | 154 | 0.050 |
Why?
|
| Centrosome | 1 | 2003 | 35 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 2054 | 0.050 |
Why?
|
| S Phase | 1 | 2003 | 73 | 0.050 |
Why?
|
| Cocarcinogenesis | 2 | 2010 | 23 | 0.050 |
Why?
|
| Alternative Splicing | 1 | 2005 | 352 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 1707 | 0.050 |
Why?
|
| Microtubule Proteins | 1 | 2003 | 27 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2003 | 303 | 0.050 |
Why?
|
| Antioxidants | 1 | 2005 | 369 | 0.050 |
Why?
|
| Secondary Prevention | 2 | 2020 | 217 | 0.050 |
Why?
|
| Transcription Factor AP-1 | 3 | 1999 | 109 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2003 | 345 | 0.050 |
Why?
|
| Random Allocation | 1 | 2003 | 440 | 0.050 |
Why?
|
| Blotting, Northern | 2 | 2001 | 261 | 0.050 |
Why?
|
| Quality of Life | 1 | 2011 | 1939 | 0.050 |
Why?
|
| Transcription, Genetic | 4 | 2005 | 1701 | 0.050 |
Why?
|
| Medical Oncology | 2 | 2015 | 215 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2003 | 294 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 1112 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 386 | 0.040 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2020 | 15 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2003 | 613 | 0.040 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2020 | 51 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2005 | 256 | 0.040 |
Why?
|
| Genes, fos | 2 | 1999 | 17 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 1254 | 0.040 |
Why?
|
| Protein Biosynthesis | 2 | 2015 | 663 | 0.040 |
Why?
|
| Biomarkers | 1 | 2008 | 3081 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2023 | 6154 | 0.040 |
Why?
|
| Microarray Analysis | 2 | 2011 | 229 | 0.040 |
Why?
|
| Ribonucleases | 1 | 1999 | 52 | 0.040 |
Why?
|
| Immunoglobulin G | 2 | 2020 | 777 | 0.040 |
Why?
|
| Growth Inhibitors | 1 | 1999 | 38 | 0.040 |
Why?
|
| Molecular Biology | 2 | 2004 | 79 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2023 | 16326 | 0.040 |
Why?
|
| Societies, Medical | 2 | 2015 | 696 | 0.040 |
Why?
|
| Chorionic Gonadotropin | 1 | 1999 | 77 | 0.040 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1999 | 63 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 238 | 0.040 |
Why?
|
| United States | 4 | 2019 | 10912 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2001 | 683 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 1958 | 0.040 |
Why?
|
| Sarcoma, Kaposi | 1 | 1999 | 119 | 0.040 |
Why?
|
| Mass Screening | 2 | 2015 | 785 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2013 | 4531 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2013 | 3892 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 1999 | 680 | 0.030 |
Why?
|
| GTP-Binding Proteins | 2 | 2008 | 179 | 0.030 |
Why?
|
| Oncogene Proteins v-mos | 1 | 1995 | 1 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 542 | 0.030 |
Why?
|
| SEER Program | 2 | 2008 | 202 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2003 | 1895 | 0.030 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1995 | 40 | 0.030 |
Why?
|
| Genes, myc | 1 | 1996 | 100 | 0.030 |
Why?
|
| Protein Binding | 2 | 2013 | 1757 | 0.030 |
Why?
|
| Carcinogens | 1 | 1996 | 152 | 0.030 |
Why?
|
| Odds Ratio | 1 | 1998 | 1256 | 0.030 |
Why?
|
| Gene Amplification | 1 | 1996 | 230 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 4403 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2010 | 1357 | 0.030 |
Why?
|
| Mutation | 3 | 1999 | 5848 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2011 | 618 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 359 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1997 | 237 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2020 | 721 | 0.030 |
Why?
|
| Cetuximab | 1 | 2012 | 13 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2012 | 14 | 0.030 |
Why?
|
| Transcriptional Activation | 2 | 2005 | 487 | 0.030 |
Why?
|
| Age Factors | 2 | 2011 | 2817 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 198 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 813 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2010 | 2397 | 0.020 |
Why?
|
| Prognosis | 3 | 2007 | 4638 | 0.020 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1991 | 11 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2012 | 135 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 143 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 504 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2006 | 867 | 0.020 |
Why?
|
| Cross Reactions | 1 | 1991 | 192 | 0.020 |
Why?
|
| Everolimus | 1 | 2011 | 49 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2004 | 1632 | 0.020 |
Why?
|
| Acne Vulgaris | 1 | 2010 | 21 | 0.020 |
Why?
|
| Urinary Bladder Diseases | 1 | 2010 | 35 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 755 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 282 | 0.020 |
Why?
|
| Antigens, CD | 1 | 1991 | 432 | 0.020 |
Why?
|
| Connexin 26 | 1 | 2008 | 14 | 0.020 |
Why?
|
| Pneumonectomy | 1 | 2010 | 143 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 2717 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1991 | 436 | 0.020 |
Why?
|
| Cell Separation | 1 | 2009 | 228 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 540 | 0.020 |
Why?
|
| Connexins | 1 | 2008 | 60 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2011 | 888 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 1999 | 62 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 899 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 475 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2010 | 351 | 0.020 |
Why?
|
| RNA | 1 | 2011 | 571 | 0.020 |
Why?
|
| Hindlimb | 1 | 1987 | 80 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 284 | 0.020 |
Why?
|
| Locomotion | 1 | 1987 | 68 | 0.020 |
Why?
|
| Sensory Receptor Cells | 1 | 1987 | 53 | 0.020 |
Why?
|
| Binding Sites | 2 | 2003 | 1303 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 1016 | 0.020 |
Why?
|
| Muscles | 1 | 1987 | 292 | 0.020 |
Why?
|
| Genes, ras | 2 | 1997 | 100 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 1241 | 0.020 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2006 | 7 | 0.020 |
Why?
|
| Risk Factors | 2 | 2015 | 10284 | 0.020 |
Why?
|
| Receptor Cross-Talk | 1 | 2006 | 38 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2006 | 58 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 363 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 656 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 63 | 0.020 |
Why?
|
| Receptors, Prostaglandin | 1 | 2005 | 22 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2007 | 230 | 0.020 |
Why?
|
| Lipocalins | 1 | 2005 | 30 | 0.020 |
Why?
|
| Base Sequence | 2 | 2003 | 3102 | 0.020 |
Why?
|
| Keratin-15 | 1 | 2005 | 1 | 0.020 |
Why?
|
| Keratin-5 | 1 | 2005 | 9 | 0.020 |
Why?
|
| Biotinylation | 1 | 2005 | 22 | 0.020 |
Why?
|
| Densitometry | 1 | 2005 | 25 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2005 | 81 | 0.010 |
Why?
|
| Luciferases, Firefly | 1 | 2004 | 14 | 0.010 |
Why?
|
| Luminescent Agents | 1 | 2004 | 7 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2005 | 112 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2006 | 897 | 0.010 |
Why?
|
| Age of Onset | 1 | 2006 | 592 | 0.010 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2006 | 296 | 0.010 |
Why?
|
| Culture Media | 1 | 2005 | 182 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 471 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 2005 | 196 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2006 | 369 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2004 | 57 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 2004 | 41 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 2062 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2004 | 256 | 0.010 |
Why?
|
| Image Cytometry | 1 | 2003 | 14 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1987 | 1016 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2005 | 302 | 0.010 |
Why?
|
| Hydroxyprostaglandin Dehydrogenases | 1 | 2003 | 2 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 330 | 0.010 |
Why?
|
| Keratin-20 | 1 | 2003 | 13 | 0.010 |
Why?
|
| Intermediate Filament Proteins | 1 | 2003 | 26 | 0.010 |
Why?
|
| Stathmin | 1 | 2003 | 2 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 1399 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 539 | 0.010 |
Why?
|
| Rats | 2 | 2003 | 3717 | 0.010 |
Why?
|
| Cattle | 1 | 2004 | 569 | 0.010 |
Why?
|
| Tubulin | 1 | 2003 | 103 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2003 | 106 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2003 | 106 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 1020 | 0.010 |
Why?
|
| Karyotyping | 1 | 2003 | 323 | 0.010 |
Why?
|
| Luciferases | 1 | 2003 | 132 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2005 | 355 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2012 | 4814 | 0.010 |
Why?
|
| Aneuploidy | 1 | 2003 | 152 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 156 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 409 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2003 | 320 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 1437 | 0.010 |
Why?
|
| Sex Factors | 1 | 2006 | 1287 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 657 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2003 | 381 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 767 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2003 | 290 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 389 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 763 | 0.010 |
Why?
|
| Proteomics | 1 | 2005 | 500 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2001 | 96 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2001 | 104 | 0.010 |
Why?
|
| Sodium Selenite | 1 | 2000 | 1 | 0.010 |
Why?
|
| Macrophages | 1 | 2005 | 622 | 0.010 |
Why?
|
| Receptors, Androgen | 1 | 2004 | 414 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2001 | 457 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 4390 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 2003 | 2521 | 0.010 |
Why?
|
| Vimentin | 1 | 1999 | 66 | 0.010 |
Why?
|
| Estrogen Antagonists | 1 | 1999 | 103 | 0.010 |
Why?
|
| Eosinophil-Derived Neurotoxin | 1 | 1999 | 3 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1999 | 54 | 0.010 |
Why?
|
| eIF-2 Kinase | 1 | 1999 | 35 | 0.010 |
Why?
|
| Fluorescence | 1 | 1999 | 96 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 1894 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 3570 | 0.010 |
Why?
|
| Observer Variation | 1 | 1999 | 299 | 0.010 |
Why?
|
| Tamoxifen | 1 | 1999 | 363 | 0.010 |
Why?
|
| Inflammation | 1 | 2005 | 1444 | 0.010 |
Why?
|
| DNA Damage | 1 | 2000 | 513 | 0.010 |
Why?
|
| DNA Probes, HPV | 1 | 1997 | 2 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2000 | 618 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2004 | 1501 | 0.010 |
Why?
|
| Estrogens | 1 | 1999 | 504 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 1997 | 79 | 0.010 |
Why?
|
| Transformation, Genetic | 1 | 1996 | 35 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1996 | 71 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 3299 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 1997 | 101 | 0.010 |
Why?
|
| Dimerization | 1 | 1996 | 144 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 1727 | 0.010 |
Why?
|
| Cell Movement | 1 | 1999 | 847 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1997 | 204 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 1999 | 795 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1995 | 121 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 1995 | 89 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1996 | 581 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1997 | 794 | 0.010 |
Why?
|
| Protein Kinases | 1 | 1995 | 332 | 0.010 |
Why?
|
| Proteins | 1 | 1999 | 1036 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1997 | 723 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1999 | 2890 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1991 | 48 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1997 | 1024 | 0.010 |
Why?
|
| CD5 Antigens | 1 | 1991 | 36 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1991 | 212 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1991 | 207 | 0.010 |
Why?
|
| Phenotype | 1 | 1999 | 4260 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1991 | 702 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 1996 | 2047 | 0.000 |
Why?
|
| Denervation | 1 | 1987 | 29 | 0.000 |
Why?
|
| Electromyography | 1 | 1987 | 165 | 0.000 |
Why?
|
| Feedback | 1 | 1987 | 164 | 0.000 |
Why?
|
| Pregnancy | 1 | 1999 | 7194 | 0.000 |
Why?
|